Literature DB >> 27018809

INCIDENCE OF LENS TOUCH DURING PARS PLANA VITRECTOMY AND OUTCOMES FROM SUBSEQUENT CATARACT SURGERY.

Zine Elhousseini1, Edward Lee, Tom H Williamson.   

Abstract

PURPOSE: To determine the incidence of lens touch during pars plana vitrectomy (PPV) and evaluate cataract surgery complications after lens touch.
METHODS: One thousand three hundred and ninety nine phakic patients who underwent PPV during the period from 2001 to 2013 were included in the study. Data of the PPV and lens touch (excluding lens bite) complications were reviewed from an electronic database (VITREOR). Subsequent cataract surgery data and intraoperative complications were reviewed. A control group consisted of 149 cases of phakic patients who underwent PPV with no lens touch then subsequent cataract surgery. All surgeries were performed by senior surgeons, and no cataract was present before the PPV.
RESULTS: The incidence of lens touch was 3.7% (52 of 1,399 phakic patients). The Demographics and presenting complaints of the patients were not significantly associated with lens touch, but retinal detachment with proliferative vitreoretinopathy, the use of silicone oil and use of relaxing retinectomy were associated with more lens touch. Cataract developed in 49 patients of whom 45 underwent cataract surgery. Nuclear sclerosis developed in 22 patients, 16 had posterior subcapsular, 8 had mixed lens opacities, and 3 had white cataract. The median duration between PPV and cataract surgery was 4 months in the lens touch group, which was significantly shorter than the median of 8 months in the control group (P = 0.001). During the subsequent cataract surgery in the lens touch group, 5 patients (11%) had a posterior capsule rupture, whereas the control group had only 2 cases of posterior capsule rupture 1.4% (P = 0.008). Final visual acuity was 0.3 LogMar or better in 22 patients (44%).
CONCLUSION: Lens touch is a frequent complication of PPV in a phakic eye. It is more common in patients having surgery for proliferative vitreoretinopathy. Care should be taken when performing subsequent cataract surgery on an eye with lens touch as it carries a significantly increased chance of posterior capsule rupture.

Entities:  

Mesh:

Year:  2016        PMID: 27018809     DOI: 10.1097/IAE.0000000000000779

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

1.  Beneficial visual outcome of vitrectomy and delamination surgery for tractional complications of diabetic retinopathy in a cohort of black patients.

Authors:  Jason Ho; Tom H Williamson; Roger S Wong; D Alistair H Laidlaw
Journal:  Eye (Lond)       Date:  2019-07-03       Impact factor: 3.775

2.  Vitrectomy versus Phaco-vitrectomy.

Authors:  Ahmed Sulaiman Al-Hinai
Journal:  Oman J Ophthalmol       Date:  2019 May-Aug

3.  Comparative study of combined vitrectomy with phacoemulsification versus vitrectomy alone for primary full-thickness macular hole repair.

Authors:  Christophe Valmaggia; Filip Kostadinov; Corina Lang; Josef Guber
Journal:  BMC Ophthalmol       Date:  2021-04-10       Impact factor: 2.209

4.  In the Right Place, at the Right Time: Autobiographical Case Report of an Ophthalmologist Who Had a Rhegmatogenous Retinal Detachment.

Authors:  Charisma Evangelista
Journal:  Cureus       Date:  2022-01-14

5.  Visual outcome and complications of cataract extraction after pars plana vitrectomy.

Authors:  Amanda Rey; Ignasi Jürgens; Xavier Maseras; Agnieszka Dyrda; Patricia Pera; Antonio Morilla
Journal:  Clin Ophthalmol       Date:  2018-05-25

Review 6.  Rhegmatogenous retinal detachment: a review of current practice in diagnosis and management.

Authors:  Ziyaad Nabil Sultan; Eleftherios I Agorogiannis; Danilo Iannetta; David Steel; Teresa Sandinha
Journal:  BMJ Open Ophthalmol       Date:  2020-10-09

7.  Fibrotic cataract as a sign of posterior capsule violation post vitrectomy.

Authors:  Eric R Williams; Jesse M Smith; Michael Huvard; Cristos Ifantides
Journal:  Am J Ophthalmol Case Rep       Date:  2021-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.